KORU Medical Systems, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Shareholders held on May 19, 2026. The filing details the voting outcomes for five proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
Shareholders voted on five key proposals with the following outcomes:
- Proposal 1 (Election of Directors): All seven nominees were elected. Total shares voted were 36,678,784. Broker non-votes totaled 10,820,650 for all nominees.
- Proposal 2 (Equity Plan Amendment): Shareholders approved an amendment to the 2024 Omnibus Equity Incentive Plan to increase the available number of shares. Votes: 25,018,973 For; 826,145 Against.
- Proposal 3 (Executive Compensation): Shareholders provided advisory approval of executive officer compensation. Votes: 25,723,379 For; 91,649 Against.
- Proposal 4 (Compensation Vote Frequency): Shareholders approved holding future advisory votes on executive compensation every one year. Votes: 24,865,692 for 1 Year; 916,055 for 3 Years.
- Proposal 5 (Auditor Ratification): Shareholders ratified the appointment of Cherry Bekaert LLP as the independent registered public accountants for the 2026 fiscal year. Votes: 36,500,510 For; 19,629 Against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard voting results.
Key Facts for Investor Verification
- Verify the specific number of shares added to the 2024 Omnibus Equity Incentive Plan following the approval of Proposal 2.
- Confirm the total number of shares outstanding and the percentage of ownership represented by the 10,820,650 broker non-votes.
- Review the full proxy statement for details on the specific compensation packages approved under Proposal 3.
- Check subsequent filings for the official appointment letter or engagement terms with Cherry Bekaert LLP.